Literature DB >> 19847677

Acute granulomatous acanthamoeba encephalitis in an immunocompetent patient.

Peter Lackner1, Ronny Beer, Gregor Broessner, Raimund Helbok, Bettina Pfausler, Christian Brenneis, Herbert Auer, Julia Walochnik, Erich Schmutzhard.   

Abstract

BACKGROUND: Acanthamoeba sp. are known to cause fatal granulomatous Acanthamoeba encephalitis (GAE) in immunocompromised patients.
METHODS: The case of a 17 year old immunocompetent patient with acute purulent meningoencephalitis is reported.
RESULTS: After substantial improvement of cerebrospinal fluid under conventional antimicrobial treatment the patient was suffering several relapses. The causative agent was identified as Acanthamoeba lenticulata T5 which entered the CNS through a bone dehiscence of ethmoidal cells. Due to severe vasospasm the patient developed multiple strokes, which led to marked neurologic sequels.
CONCLUSIONS: This case report demonstrates successful treatment of usually lethal GAE in an immunocompetent patient with high dose meropenem, linezolid, moxifloxacin and fluconazole followed by a partially adapted antimicrobial combination therapy.

Entities:  

Mesh:

Year:  2010        PMID: 19847677     DOI: 10.1007/s12028-009-9291-z

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  9 in total

1.  Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials.

Authors:  T Singhal; A Bajpai; V Kalra; S K Kabra; J C Samantaray; G Satpathy; A K Gupta
Journal:  Pediatr Infect Dis J       Date:  2001-06       Impact factor: 2.129

2.  HARTMANELLA CASTELLANI (ACANTHAMOEBA SP): PRELIMINARY REPORT ON EXPERIMENTAL CHEMOTHERAPY.

Authors:  C G CULBERTSON; D H HOLMES; W M OVERTON
Journal:  Am J Clin Pathol       Date:  1965-04       Impact factor: 2.493

3.  The prevalence of Acanthamoeba in the human environment.

Authors:  H Mergeryan
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

4.  Protective and curative effects of rifampicin in Acanthamoeba meningitis of the mouse.

Authors:  S R Das; S Asiri; A el-Soofi; H P Baer
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

5.  Early diagnosis of Acanthamoeba infection during routine cytological examination of cerebrospinal fluid.

Authors:  Franz Petry; Michael Torzewski; Jürgen Bohl; Thomas Wilhelm-Schwenkmezger; Patrick Scheid; Julia Walochnik; Rolf Michel; Lothar Zöller; Konrad J Werhahn; Sucharit Bhakdi; Karl J Lackner
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

6.  Pediatric granulomatous cerebral amebiasis: a delayed diagnosis.

Authors:  Marcelo Galarza; Vicente Cuccia; Fidel P Sosa; Jorge A Monges
Journal:  Pediatr Neurol       Date:  2002-02       Impact factor: 3.372

Review 7.  Acanthamoeba, an opportunistic microorganism: a review.

Authors:  A J Martinez; K Janitschke
Journal:  Infection       Date:  1985 Nov-Dec       Impact factor: 3.553

Review 8.  Opportunistic amoebae: challenges in prophylaxis and treatment.

Authors:  Frederick L Schuster; Govinda S Visvesvara
Journal:  Drug Resist Updat       Date:  2004-02       Impact factor: 18.500

Review 9.  Disseminated cutaneous acanthamebiasis: a case report and review of the literature.

Authors:  Michael Paltiel; Eric Powell; Jane Lynch; Bryan Baranowski; Ciro Martins
Journal:  Cutis       Date:  2004-04
  9 in total
  19 in total

1.  Resistance of Acanthamoeba cysts to disinfection treatments used in health care settings.

Authors:  Céline Coulon; Anne Collignon; Gerald McDonnell; Vincent Thomas
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

2.  Emerging and reemerging neurologic infections.

Authors:  Felicia C Chow; Carol A Glaser
Journal:  Neurohospitalist       Date:  2014-10

Review 3.  The Development of Drugs against Acanthamoeba Infections.

Authors:  Ruqaiyyah Siddiqui; Yousuf Aqeel; Naveed Ahmed Khan
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Therapeutic potential of a combination of two gene-specific small interfering RNAs against clinical strains of Acanthamoeba.

Authors:  Jacob Lorenzo-Morales; Carmen M Martín-Navarro; Atteneri López-Arencibia; María A Santana-Morales; Raquel N Afonso-Lehmann; Sutherland K Maciver; Basilio Valladares; Enrique Martínez-Carretero
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 5.  Various brain-eating amoebae: the protozoa, the pathogenesis, and the disease.

Authors:  Hongze Zhang; Xunjia Cheng
Journal:  Front Med       Date:  2021-11-26       Impact factor: 4.592

6.  Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba.

Authors:  C M Martín-Navarro; A López-Arencibia; F Arnalich-Montiel; B Valladares; J E Piñero; J Lorenzo-Morales
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-19       Impact factor: 3.117

7.  Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier.

Authors:  Duncan Webster; Imran Umar; Imram Umar; George Kolyvas; Juan Bilbao; Marie-Christine Guiot; Kevin Duplisea; Yvonne Qvarnstrom; Govinda S Visvesvara
Journal:  Am J Trop Med Hyg       Date:  2012-08-06       Impact factor: 2.345

8.  Evaluation of inhibitory potential of some selective methanolic plants extracts on biological characteristics of Acanthamoeba castellanii using human corneal epithelial cells in vitro.

Authors:  Hafiz Muhammad Shoaib; Ambreen Gul Muazzam; Asif Mir; Suk-Yul Jung; Abdul Matin
Journal:  Parasitol Res       Date:  2013-01-10       Impact factor: 2.289

Review 9.  Twenty years of acanthamoeba diagnostics in Austria.

Authors:  Julia Walochnik; Ute Scheikl; Eva-Maria Haller-Schober
Journal:  J Eukaryot Microbiol       Date:  2014-09-25       Impact factor: 3.346

Review 10.  Drugs used for the treatment of cerebral and disseminated infections caused by free-living amoebae.

Authors:  Alexandre Taravaud; Zineb Fechtali-Moute; Philippe M Loiseau; Sébastien Pomel
Journal:  Clin Transl Sci       Date:  2021-03-01       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.